Investigational drug · Phase 2
Alisertib
Also called: PB-8237, MLN8237
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
65
Any phase or sponsor naming "Alisertib"
First trial start
2024
Feb 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Alisertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer
- Small Cell Lung Cancer
- Small Cell Lung Cancer ( SCLC )
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Alisertib" as an intervention, largest first.
- Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01045421 · 273 participants · Start Feb 2010 · Primary completion May 2013
Drug: MLN8237 (Alisertib) · For: Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer and 3 more
Sites: Houston, Texas; Salt Lake City, Utah
- Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01482962 · 271 participants · Start Jun 11, 2012 · Primary completion Jun 30, 2015
Drug: Alisertib; Pralatrexate and 2 more · For: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Sites: Birmingham, Alabama; La Jolla, California; Orlando, Florida · 151 sites in all
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPivotal-lookingRecruiting
Puma Biotechnology, Inc.Industry
NCT06369285 · 225 participants (planned) · Start Nov 19, 2024 · Primary completion Dec 30, 2027
Drug: Alisertib; Endocrine therapy · For: Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 53 sites in all
- Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01091428 · 191 participants · Start Apr 16, 2010 · Primary completion Aug 12, 2014
Drug: Alisertib; Paclitaxel · For: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer and 1 more
Sites: The Bronx, New York; Philadelphia, Pennsylvania; Houston, Texas · 4 sites in all
- Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)Pivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02038647 · 178 participants · Start May 12, 2014 · Primary completion Jan 3, 2016
Drug: Alisertib; Placebo and 1 more · For: Small Cell Lung Cancer
Sites: Los Angeles, California; Sacramento, California; New Haven, Connecticut · 61 sites in all
- Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerPivotal-lookingCompleted
US Oncology ResearchIndustry
NCT02187991 · 169 participants · Start Feb 12, 2015 · Primary completion Apr 11, 2024
Drug: Paclitaxel; Alisertib · For: Breast Cancer; Breast Carcinoma; Breast Tumors and 1 more
Sites: Including Dallas and Austin, Texas
- Phase 2 Study of Alisertib Therapy for Rhabdoid TumorsActive, not recruiting
St. Jude Children's Research HospitalAcademic, hospital or other
NCT02114229 · 125 participants · Start May 14, 2014 · Primary completion Sep 30, 2025
Drug: alisertib; methotrexate and 6 more · For: Malignant Rhabdoid Tumor; Atypical Teratoid Rhabdoid Tumor
Sites: Palo Alto, California; San Diego, California; Aurora, Colorado · 9 sites in all
Puma Biotechnology, Inc.Industry
NCT06095505 · 120 participants (planned) · Start Feb 8, 2024 · Primary completion Oct 30, 2027
Drug: Alisertib · For: Small Cell Lung Cancer
Sites: Daphne, Alabama; Long Beach, California; Lone Tree, Colorado · 30 sites in all
Children's Oncology GroupResearch network
NCT01154816 · 118 participants · Start Feb 2011 · Primary completion Dec 31, 2015
Drug: Alisertib · For: Hepatoblastoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Childhood Acute Lymphoblastic Leukemia and 8 more
Sites: Birmingham, Alabama; Little Rock, Arkansas; Downey, California · 105 sites in all
Mayo ClinicAcademic, hospital or other
NCT02860000 · 96 participants · Start Jul 6, 2017 · Primary completion Jan 10, 2022
Drug: Alisertib; Fulvestrant · For: Estrogen Receptor Status; HER2/Neu Negative; Invasive Breast Carcinoma and 6 more
Sites: Washington D.C., District of Columbia; Boston, Massachusetts; Ann Arbor, Michigan · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Integrative Systems Biology Prioritizes BCL2, ALK, and CDK4 as Therapeutic Candidates in Neuroblastoma through Multi-Centrality Network Analysis, Cross-Database Validation, Independent Docking Validation, and Confidence-Threshold Sensitivity Analysis.
Zabihi A · Comput Biol Chem 2027
- QW-5-70 Targets the Colchicine Site and Demonstrates Antitumor Activity in P-gp-Overexpressing Cancer Models.
Xie Y, Hou R, Albadari N, et al. · Mol Cancer Ther 2026
- Inhibition of Aurora Kinase A Prevents Malignant Transformation in Oral Leukoplakia.
Yin F, Li M, Xu Y, et al. · J Oral Pathol Med 2026
- Nanoparticles-mediated dual drug administration boosts therapeutic efficacy in drug resistant melanoma.
Lovati G, Milesi P, Fossati P, et al. · J Control Release 2026
- α7 integrin co-regulates chromatin accessibility and gene expression in HPV-negative head and neck cancer.
Borodins O, Vehlow A, Sameith K, et al. · Signal Transduct Target Ther 2026
- An entosis-informed prognostic index for survival stratification and molecular characterization in lung adenocarcinoma.
Liu Y, Zhao W, Mu S, et al. · Front Cell Dev Biol 2026
Also in development for Hormone Receptor Positive HER-2 Negative Breast Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- EP0062Phase 21 trial
Ellipses Pharma · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.